glp-1 fda approval Lilly is now pharma's top revenue company. It just got for an oral GLP-1, but Wall Street isn't celebrating FDA approves first generic GLP-1

A number of studies dedicated to GLP-1RA efficacy in T2D included patients with chronic HF (CHF) (16.2% in the EXSCEL trial, 23.6% in SUSTAIN-6, 12.2% in PIONEER, 8.6% in REWIND, 20% in Harmony, 22% in ELIXA and 18% in LEADER)

10 , 17 If the dose is fixed at 2.4 mg but the dosing interval is increased to 14 days (q2wk), the model predicts a steadystate body weight reduction of 12%

By the end of the study, the ICP in exenatide users decreased by 5.6 3.0 cmCSF compared with controls ( P = .058)

Moens K, Heimberg H, Flamez D et al

(2021) Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial